105 related articles for article (PubMed ID: 10590284)
21. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients.
Rolston KV; Frisbee-Hume S; LeBlanc B; Streeter H; Ho DH
Diagn Microbiol Infect Dis; 2003 Oct; 47(2):441-9. PubMed ID: 14522520
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of the new quinolone moxifloxacin (Bay 12-8039) against resistant gram-positive clinical isolates.
Alcalá L; Cercenado E; García-Garrote F; Bouza E
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):27-31. PubMed ID: 9990472
[TBL] [Abstract][Full Text] [Related]
23. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
Morrissey I; Robbins M; Viljoen L; Brown DF
J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
[TBL] [Abstract][Full Text] [Related]
24. Antibacterial activity of moxifloxacin against periodontal anaerobic pathogens involved in systemic infections.
Milazzo I; Blandino G; Musumeci R; Nicoletti G; Lo Bue AM; Speciale A
Int J Antimicrob Agents; 2002 Dec; 20(6):451-6. PubMed ID: 12458140
[TBL] [Abstract][Full Text] [Related]
25. [In vitro activity of moxifloxacin against respiratory pathogens in Latin America].
López H; Sader H; Amábile C; Pedreira W; Muñoz Bellido JL; García Rodríguez JA;
Rev Esp Quimioter; 2002 Dec; 15(4):325-34. PubMed ID: 12587037
[TBL] [Abstract][Full Text] [Related]
26. RO 23-9424, a new cephalosporin 3'-quinolone: in-vitro antimicrobial activity and tentative disc diffusion interpretive criteria.
Pfaller MA; Barry AL; Fuchs PC
J Antimicrob Chemother; 1993 Jan; 31(1):81-8. PubMed ID: 8444677
[TBL] [Abstract][Full Text] [Related]
27. [National multicenter study of the in vitro activity of moxifloxacin against respiratory tract pathogens. Spanish Study Group on Moxifloxacin].
Loza E; Morosini M; Negri MC; Almaraz F; Cantón R; Baquero F
Rev Esp Quimioter; 2000 Mar; 13(1):37-43. PubMed ID: 10855023
[TBL] [Abstract][Full Text] [Related]
28. Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method.
Hope R; Parsons T; Mushtaq S; James D; Livermore DM
J Antimicrob Chemother; 2007 Oct; 60(4):770-4. PubMed ID: 17704517
[TBL] [Abstract][Full Text] [Related]
29. The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone.
Wise R; Andrews JM
J Antimicrob Chemother; 1999 Nov; 44(5):679-88. PubMed ID: 10552986
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of moxifloxacin, a new 8-methoxyquinolone, against gram-positive bacteria.
Malathum K; Singh KV; Murray BE
Diagn Microbiol Infect Dis; 1999 Oct; 35(2):127-33. PubMed ID: 10579093
[TBL] [Abstract][Full Text] [Related]
31. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
[TBL] [Abstract][Full Text] [Related]
32. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin.
MacGowan A; Rogers C; Holt HA; Wootton M; Bowker K
J Antimicrob Chemother; 2000 Jul; 46(1):73-8. PubMed ID: 10882692
[TBL] [Abstract][Full Text] [Related]
33. Validation of EUCAST zone diameter breakpoints against reference broth microdilution.
Bengtsson S; Bjelkenbrant C; Kahlmeter G
Clin Microbiol Infect; 2014 Jun; 20(6):O353-60. PubMed ID: 24118469
[TBL] [Abstract][Full Text] [Related]
34. BSAC standardized disc susceptibility testing method (version 8).
Andrews JM;
J Antimicrob Chemother; 2009 Sep; 64(3):454-89. PubMed ID: 19587067
[TBL] [Abstract][Full Text] [Related]
35. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
Firsov AA; Lubenko IY; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
[TBL] [Abstract][Full Text] [Related]
36. [Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
Yamaguchi K; Miyazaki S; Kashitani F; Iwata M; Kanda M; Tsujio Y; Okada J; Tazawa Y; Watanabe N; Uehara N; Igari J; Oguri T; Kaimori M; Kawamura C; Iinuma Y; Nisawataira T; Tashiro H; Ueno K; Ishigo S; Yasujima M; Kawahara S; Itoh C; Yoshida T; Yamanaka K; Toyoshima S; Katoh J; Kudoh M; Matsushima T; Niki Y; Miyashita N; Funato T; Kaku M; Sato N; Saito Y; Ishii K; Kuwabara M; Hongo T; Negayama K; Kamihira S; Miyazaki Y; Takii M; Ishii M; Nakagawa K; Ono J; Takada T; Murakami N; Taira M; Tamaki I; Matsudou Y; Nakasone I
Jpn J Antibiot; 2000 Jun; 53(6):387-408. PubMed ID: 10955236
[TBL] [Abstract][Full Text] [Related]
37. Comparative bactericidal activity of fluoroquinolones against clinical isolates resistant to fluoroquinolones.
Drago L; De Vecchi E; Nicola L; Valli M; Marchetti F; Gismondo MR
J Chemother; 2003 Apr; 15(2):118-23. PubMed ID: 12797386
[TBL] [Abstract][Full Text] [Related]
38. Influence of moxifloxacin, comparator drugs and some fractions of pulmonary surfactant on adherence of some respiratory pathogens.
Ferrara A; Dos Santos C; Tellarini MT
Infection; 2002 Aug; 30(4):208-11. PubMed ID: 12236562
[TBL] [Abstract][Full Text] [Related]
39. [In vitro antibacterial activity of a new fluoroquinolone, sparfloxacin, against nosocomial bacteria, and concordance curve].
Soussy CJ; Cluzel M; Derlot E; Exmelin L; Kitzis MD; Dabernat H; Le Noc P; Muller-Serieys C; Reverdy ME; Scheftel JM; Thabaut A
Pathol Biol (Paris); 1996 Apr; 44(4):241-8. PubMed ID: 8763585
[TBL] [Abstract][Full Text] [Related]
40. [Moxifloxacin--antimicrobial activity and pharmacokinetic properties].
Iakovlev VP; Polushkina NR
Antibiot Khimioter; 2002; 47(5):19-29. PubMed ID: 12365324
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
